Both SAHA and VPA display antitumor activity in vivo with a favorable pharmacological profile and well-tolerated side effects.19, 20 In addition, HDACis might sensitize malignant cells to NK cell recognition depending on NKG2D–NKG2DL signaling.21, 22 These data suggest that HDACis may serve as a new and tumor-selective drug class by enhancing immune surveillance in the treatment of BC. The gene discussed is KLRK1; the disease is breast cancer.